NEWS

Longeviti Launches ClearFit AI Platform for Bedside Brain Ultrasound Access

Shots: Longeviti Neuro has launched ClearFit AI, a Brain Ultrasound Interface, creating a persistent acoustic window to the brain to enable real-time bedside ultrasound imaging after neurosurgery ClearFit AI combines sonolucent cranial implants, ultrasound compatibility, clinical workflow support, & AI-enhanced imaging to enable bedside brain assessment within existing neuro care workflows, potentially reducing CT/MRI transport…

July 8, 2026

OTR Therapeutics Partners with LG Chem to Develop Novel Oncology Therapies

Shots: OTR has partnered with LG Chem to identify, evaluate & develop novel oncology assets from China, leveraging OTR's R&D platform & LG Chem's global development expertise & commercial infrastructure As per the deal, OTR will identify & advance oncology assets through early clinical development in China, while LG Chem will jointly evaluate & license…

July 8, 2026

Vera Therapeutics Reports the US FDA Accelerated Approval of Trutakna (Atacicept) to Treat IgA Nephropathy

Shots: The US FDA has granted accelerated approval to Trutakna to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk for disease progression Approval was supported by the ongoing global P-III (ORIGIN 3) trial evaluating atacicept (150mg, SC, QW) vs PBO in adults with IgAN, assessing eGFR-based kidney function over 2yrs., with…

July 8, 2026

Agios Pharmaceuticals Receives US FDA Priority Review for Mitapivat to Treat Sickle Cell Disease

Shots: The US FDA has accepted the sNDA & granted priority review to mitapivat, under FDA’s accelerated approval pathway, for the treatment of Sickle Cell Disease (PDUFA: Nov 1, 2026) sNDA was supported by the global P-II/III (RISE UP) trial assessing mitapivat (100mg, PO, BID; n=138) vs PBO (n=69) in 207 pts with SCD (≥16yrs.)…

July 7, 2026

Splash Licenses Argent BioPharma’s CannEpil for Global Epilepsy Rights

Shots: Splash secured exclusive global rights to develop & commercialize CannEpil for drug-resistant epilepsy, refractory epilepsy, seizure disorders, & related neurological conditions, incl. future product improvements & next-generation formulations Splash secured a $1M strategic investment from C/M Capital Partners, while Mercer Street forgave ~$5M in Argent BioPharma debt and Splash issued $5.5M in preferred equity…

July 7, 2026

Alcon Partners with RxSight to Develop Adjustable PCIOLs

Shots: Alcon has entered into a non-exclusive collaboration with RxSight to jointly develop adjustable presbyopia-correcting intraocular lenses (PCIOLs) Under the collaboration, RxSight & Alcon will combine RxSight’s post-operative light-adjustable technology with Alcon’s PCIOL optical designs to co-develop adjustable PCIOLs for optimized cataract surgery outcomes As per the deal, RxSight will lead development & manufacturing, receiving…

July 7, 2026

Ionis Completes Patient Enrollment in Cohort 1 of P-III (REVEAL) Study of Obudanersen in Angelman syndrome (AS)

Shots: Ionis has completed enrollment in Cohort 1 (n=136; 2 to <18yrs.) of the global P-III (REVEAL) study assessing obudanersen (ION582) in pts with AS with genetic confirmation of either a UBE3A deletion or UBE3A mutation The Cohort 2 comprises adult pts (18 to ≤50yrs.) living with AS, with enrollment expected to be completed in…

July 7, 2026

AbbVie and Genmab Report EC Approval of Tepkinly Combination to Treat R/R Follicular Lymphoma

Shots: The EC has approved Tepkinly (epcoritamab) in combination with lenalidomide and rituximab (Tepkinly + R2) for the treatment of adults with R/R follicular lymphoma (FL) Approval was based on the P-III (EPCORE FL-1) trial assessing fixed-duration Tepkinly + R2 (n=243) vs SoC R2 (n=245) in pts with R/R FL following ≥1 prior line of treatment Trial…

July 7, 2026

Vertex Pharmaceuticals to Acquire Crinetics Pharmaceuticals for ~$10B

Shots: Vertex has entered into a definitive agreement to acquire Crinetics, incl. its assets Palsonify (paltusotine) & atumelnant, accelerating Vertex’s revenue growth and enhancing its long-term earnings profile As per the deal, Vertex to acquire Crinetics for $85/share in cash, representing the total equity value of ~$10B, or ~$8.8B net of estimated cash acquired Palsonify (QD, PO)…

July 7, 2026

Pharvaris Reports the US FDA’s NDA Acceptance of Deucrictibant IR for On-Demand Treatment of Hereditary Angioedema Attacks

Shots: The US FDA has accepted NDA for deucrictibant immediate-release (IR) capsule (20 mg) for the on-demand treatment of Hereditary Angioedema (HAE) attacks (PDUFA: Apr 23, 2027) NDA was backed by data from >1,300 HAE attacks. In P-III (RAPIDe-3) trial, deucrictibant IR met the 1EP & all eleven 2EPs, with median times to symptom relief,…

July 6, 2026

NEWS

Longeviti Launches ClearFit AI Platform for Bedside Brain Ultrasound Access

OTR Therapeutics Partners with LG Chem to Develop Novel Oncology Therapies

Vera Therapeutics Reports the US FDA Accelerated Approval of Trutakna (Atacicept) to Treat IgA Nephropathy

Agios Pharmaceuticals Receives US FDA Priority Review for Mitapivat to Treat Sickle Cell Disease

Splash Licenses Argent BioPharma’s CannEpil for Global Epilepsy Rights

Alcon Partners with RxSight to Develop Adjustable PCIOLs

Ionis Completes Patient Enrollment in Cohort 1 of P-III (REVEAL) Study of Obudanersen in Angelman syndrome (AS)

AbbVie and Genmab Report EC Approval of Tepkinly Combination to Treat R/R Follicular Lymphoma

Vertex Pharmaceuticals to Acquire Crinetics Pharmaceuticals for ~$10B

Pharvaris Reports the US FDA’s NDA Acceptance of Deucrictibant IR for On-Demand Treatment of Hereditary Angioedema Attacks

Contact US

FOLLOW US